TY - JOUR AB - Biliary tract cancers (BTC) are rare but aggressive. Due to limited anti‑tumor effects of current second‑ and later‑line treatment regimens, novel treatment options are required. Nanoliposomal irinotecan in combination with leucovorin and 5‑fluorouracil (FOLFnal‑IRI) achieved promising results as a second‑line treatment in patients with pancreatic cancer, warranting further investigation in BTC. In the present study, a retrospective analysis of patients receiving FOLFnal‑IRI after initial platinum‑based chemotherapy for advanced BTC between January 2016 and August 2020 at the University Hospital Cologne (Cologne, Germany) was performed. A total of 11 patients were identified who met the inclusion criteria. A total of 4 patients (36.4%) were female and the median age was 54 years. The proportion of patients suffering from gallbladder carcinoma, intrahepatic and extrahepatic cholangiocarcinoma was 18.2, 63.6 and 9.1%, respectively. Furthermore, 7 patients (63.6%) received FOLFnal‑IRI as their second‑, 3 (27.3%) as third‑ and one (9.1%) as their fourth‑line therapy. The disease control rate was 54.5% and 3 grade III toxicities were recorded. Progression‑free survival and overall survival (OS) after initiation of FOLFnal‑IRI was 5.1 and 12.4 months, respectively. OS after initial diagnosis was 24.7 months. FOLFnal‑IRI demonstrated promising antitumor potential with an acceptable safety profile as a subsequent therapy regimen in advanced biliary tract malignancies. Further randomized controlled trials of its value as a treatment option for BTC appear justified. AD - Department for Gastroenterology and Hepatology, Faculty of Medicine, University Hospital of Cologne, University of Cologne, D-50937 Cologne, Germany Department of General, Visceral and Cancer and Transplant Surgery, University Hospital of Cologne, University of Cologne, D-50937 Cologne, Germany AU - Allo,Gabriel AU - Can,Ahu,Damla AU - Wahba,Roger AU - Vogel,Nils AU - Goeser,Tobias AU - Kütting,Fabian AU - Waldschmidt,Dirk DA - 2022/02/01 DO - 10.3892/mco.2021.2485 IS - 2 JO - Mol Clin Oncol KW - biliary tract cancer liposomal irinotecan overall survival progression free survival second‑line chemotherapy PY - 2022 SN - 2049-9450 2049-9469 SP - 52 ST - Nanoliposomal irinotecan in combination with leucovorin and 5‑fluorouracil in advanced biliary tract cancers T2 - Molecular and Clinical Oncology TI - Nanoliposomal irinotecan in combination with leucovorin and 5‑fluorouracil in advanced biliary tract cancers UR - https://doi.org/10.3892/mco.2021.2485 VL - 16 ER -